↧
Image may be NSFW.
Clik here to view.
Clik here to view.
Leerink ups Intra-Cellular target to $34 from $13
Leerink Partners has raised its price target for “outperform-rated” Intra-Cellular Therapies (NASDAQ:ITCI) to $34 from $13, after making adjustments to the revenue and expense lines in its model, which...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
Leerink ups Intra-Cellular price target to $35
Leerink Partners has raised its price target for “outperform-rated” Intra-Cellular Therapies (NASDAQ:ITCI) to $35 from $34 in assumed coverage. The stock closed at $15.98 on Tuesday. Intra-Cellular has...
View Article